A theoretical physicist by training who studies the intersection of cancer research, immunology, evolutionary theory and virology.

Benjamin D. Greenbaum is an associate attending computational oncologist at Memorial Sloan Kettering Cancer Center in the department of epidemiology and biostatistics and the inaugural program leader in computational immune-oncology. He previously worked as an associate professor at the Icahn School of Medicine at Mt. Sinai, where he conducted much of the foundational scientific research that led to the formation of ROME Therapeutics. Ben uses techniques from statistical physics, information theory and evolutionary biology to better understand the interaction of host tumoral RNA with the innate immune system, the role of tumor antigens in the evolution of tumors both generally and in response to immunotherapy, and various aspects of virus evolution. He has been named a NextGen Innovator by HemOnc Today, and was awarded the Phillip A. Sharp Award for Innovation in Collaboration from Stand Up to Cancer – where he is a co-leader of a Convergence 2.0 team studying the interactions between neoantigens and T cells in pancreatic cancer – and the Pershing Square Sohn Prize and Mark Foundation Fellowship. Ben trained in the theoretical division of Los Alamos National Laboratory and the Simons Center for Systems Biology at the Institute for Advanced Study in Princeton, where he was the Eric and Wendy Schmidt Long-Term Member. He earned his Ph.D. in theoretical physics from Columbia University, where he was also an undergraduate major in physics and philosophy of science.